Lesia K. Dropulic

Infectious Disease
600 N Wolfe St
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications

Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.

Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.

Journal: Research square
Published: December 31, 2025

Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.

Rational Design of Multiclade Coronavirus Spike Immunodominant Domain Nanoparticles to Elicit Broad Antibody Responses.

Journal: bioRxiv : the preprint server for biology
Published: November 19, 2025

Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.

Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.

Journal: The Journal of allergy and clinical immunology
Published: September 03, 2025

Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.

Targeted deep sequencing identifies mosaicism in patients with immune dysregulation.

Journal: The Journal of allergy and clinical immunology
Published: September 03, 2025

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial.

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial.

Journal: Nature medicine
Published: July 25, 2025

Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses.

Cross-neutralizing and potent human monoclonal antibodies against historical and emerging H5Nx influenza viruses.

Journal: Nature microbiology
Published: June 17, 2025

Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem-specific human B cells.

Vaccination with different group 2 influenza subtypes alters epitope targeting and breadth of hemagglutinin stem-specific human B cells.

Journal: Science translational medicine
Published: January 01, 2025

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults.

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults.

Journal: The lancet. HIV
Published: November 15, 2024

Early influenza virus exposure shapes the B cell response to influenza vaccination in individuals 50 years later.

Early influenza virus exposure shapes the B cell response to influenza vaccination in individuals 50 years later.

Journal: Immunity
Published: August 27, 2024

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.

Phase 1 dose-escalation trial evaluating a group 2 influenza hemagglutinin stabilized stem nanoparticle vaccine.

Journal: NPJ vaccines
Published: April 18, 2024

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.

Journal: Science translational medicine
Published: April 19, 2023

An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans.

An influenza H1 hemagglutinin stem-only immunogen elicits a broadly cross-reactive B cell response in humans.

Journal: Science translational medicine
Published: April 19, 2023
Showing 1-12 of 29

Last Updated: 09/26/2026